Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck KGaA, Darmstadt, Germany, has announced a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash, resulting in a total enterprise value of approximately $11.3 billion (EUR 9.9 billion). This transaction, which was publicly disclosed on June 25, 2026, represents a 36% premium over Bio-Techne's one-month volume-weighted average trading price. The acquisition is expected to be immediately accretive to sales growth and EBITDA margins post-closing, with projected annual cost synergies of around EUR 140 million anticipated by the third year after the deal's completion.

Bio-Techne, based in Minneapolis, is recognized for its extensive portfolio in life science tools, analytical technologies, and consumables. The company has established a strong reputation over its 50-year history, particularly in areas such as proteomics, spatial biology, and novel therapeutics. The acquisition by Merck KGaA aims to enhance its capabilities in high-growth sectors, including multi-omics and precision diagnostics, thereby strengthening its position along the full life science value chain.

The strategic rationale behind this acquisition is clear: Merck KGaA seeks to deepen its engagement in the life sciences market, which is characterized by rapid innovation and increasing demand for integrated solutions. By combining Bio-Techne's advanced technologies and expertise with its own global scale and manufacturing capabilities, Merck KGaA is poised to accelerate its innovation pipeline and broaden its offerings across research, bioprocessing, and advanced therapeutics. This synergy is expected to enhance customer access and improve service delivery across increasingly complex scientific workflows.

The life sciences sector is currently experiencing significant growth, driven by advancements in biotechnology and an increasing focus on personalized medicine. As companies like Merck KGaA and Bio-Techne align their resources and capabilities, they are better positioned to capitalize on emerging opportunities in areas such as cell and gene therapy. This acquisition not only reflects Merck KGaA's commitment to expanding its portfolio but also underscores the ongoing trend of consolidation in the life sciences industry as firms strive to enhance their competitive edge.

In conclusion, the acquisition of Bio-Techne by Merck KGaA represents a strategic move to solidify its leadership in the life sciences market. With the anticipated synergies and enhanced capabilities, Merck KGaA is expected to drive significant growth and innovation in the sector. As the life sciences landscape continues to evolve, this transaction may serve as a catalyst for further consolidation and partnerships, shaping the future of scientific discovery and therapeutic development.